<DOC>
	<DOCNO>NCT01549184</DOCNO>
	<brief_summary>Retrospective study safety efficacy hydroxychloroquine among patient immune Thrombopenia ( ITP ) .</brief_summary>
	<brief_title>Retrospective Analysis Safety Efficacy Hydroxychloroquine Immune Thrombocytopenia</brief_title>
	<detailed_description>Hydroxychloroquine ( HCQ ) usually use Patients Systemic Lupus Erythematosus ( SLE ) order treat mainly arthralgia skin manifestation disease . A study previously show HCQ could also useful treat autoimmune cytopenia particularly autoimmune thrombopenia associate SLE . In retrospective study , investigator select patient follow center receive HCQ either authentic SLE positive antinuclear antibody ( &gt; 1/160e HEP2 cell ) without definite SLE accord American College Rheumatology . The main goal study compare efficacy HCQ two subgroup patient .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Patients older 18 year old Immune Thrombopenia accord American Society Hematology ( ASH ) guideline 2011 Positive antinuclear antibody &gt; 1/160e Hep2 cell Secondary ITP ( eg HIV , HCV , HBV , lymphoproliferative disorder ... )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>secondary ITP</keyword>
	<keyword>hydroxychloroquine</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
</DOC>